Summit
Favicon Fierce Pharma

Summit's global PD-1xVEGF data show new promising OS trend

With a fresh data cut in September, the death risk reduction by the ivonescimab regimen expanded to 22% with an improved nominal p value of 0.0332.
Angus Liu Sep 7, 2025 3:30am
image of two race cars neck and neck

Daiichi, Merck rev up for accelerated approval filing

Sep 7, 2025 10:45am
Senseonics Eversense 365 placed on arm

Senseonics to retake Eversense commercial control from Ascensia

Sep 5, 2025 2:00pm
Medtronic Hugo robotic surgery console

Medtronic’s Hugo robot logs success in hernia repair trial

Sep 5, 2025 12:00pm
dominoes stop stall halt end red

'Several concerning observations': FDA sheds light on rejections

Sep 5, 2025 10:45am
sword fight onward path sunset sun rise

Braveheart pays $65M to challenge BMS for heart disease market

Sep 5, 2025 9:05am
More News

Merck KGaA lands new R&D chief—Chutes & Ladders

Sep 5, 2025 8:30am

BioNTech's ADC beats Roche’s Kadcyla in breast cancer phase 3

Sep 5, 2025 7:30am

Fierce Biotech Fundraising Tracker: MRM Health, Treeline & more

Sep 4, 2025 4:15pm
Fierce Pharma

RFK Jr. blasts pharma industry, touts mRNA vaccine misinformation

Sep 4, 2025 3:51pm